Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 10/07/2025
• Auteurs : Federico BellelliPhilipe Barreto de SoutoChristelle CantetPierre-Jean OussetKaj BlennowBruno VellasDavide AngioniSophie Gillette-GuyonnetIsabelle CarriéLauréane BrigitteCatherine FaisantFrançoise LalaJulien DelrieuHélène VillarsEmeline CombrouzeCarole BadufleAudrey ZuerasSandrine AndrieuChristophe MorinGabor Abellan van KanCharlotte DupuyYves RollandCeline CaillaudPierre-Jean OussetFrançoise LalaSylvie BellevilleBrigitte GilbertFrancine FontaineJean-François DartiguesIsabelle MarcetFleur DelvaAlexandra FoubertSandrine CerdaCorinne CostesOlivier RouaudPatrick ManckoundiaValérie QuipourtSophie MarilierEvelyne FranonLawrence BoriesMarie-Laure PaderMarie-France BassetBruno LapoujadeValérie FaureMichael Li Yung TongChristine Malick-LoiseauEvelyne Cazaban-CampistronFrançoise DesclauxColette BlatgeThierry DantoineCécile Laubarie-MouretIsabelle SaulnierJean-Pierre ClémentMarie-Agnès PicatLaurence Bernard-BourzeixStéphanie WilleboisIléana DésormaisNoëlle CardinaudMarc BonnefoyPierre LivetPascale RebaudetClaire GédéonCatherine BurdetFlavien TerracolAlain PesceStéphanie RothSylvie ChaillouSandrine LouchartKristel SudresNicolas LebrunNadège Barro-BelayguesJacques TouchonKarim BennysAudrey GabelleAurélia RomanoLynda TouatiCécilia MarelliCécile PaysPhilippe RobertFranck Le DuffClaire GervaisSébastien GonfrierYannick GasnierSerge BordesDanièle BegorreChristian CarpuatKhaled KhalesJean-François LefebvreSamira Misbah El IdrissiPierre SkolilJean-Pierre SallesCarole DufouilMarie ChupinJean-François ManginAli BouhayiaMichèle AllardFrédéric RicolfiDominique DuboisMarie Paule Bonceour MartelFrançois CottonAlain BonaféStéphane ChanaletFrançoise HugonFabrice BonnevilleChristophe CognardFrançois CholletPierre PayouxThierry VoisinJulien DelrieuSophie PeifferAnne HitzelMichèle AllardMichel ZancaJacques MonteilJacques DarcourtLaurent MolinierHélène DerumeauxNadège CostaBertrand PerretClaire VinelSylvie Caspar-BauguilPascale Olivier-AbbalNicola Coley
• Organismes : Institut Hospitalier Universitaire HealthAge Università degli Studi di Milano = University of Milano Institut Hospitalier Universitaire HealthAge Institut Hospitalier Universitaire HealthAge Institut Hospitalier Universitaire HealthAge Equipe AGING (CERPOP) Göteborgs Universitet = University of Gothenburg Sahlgrenska University Hospital [Gothenburg] Institut Hospitalier Universitaire HealthAge Equipe AGING (CERPOP) Institut Hospitalier Universitaire HealthAge Institut Hospitalier Universitaire HealthAge Equipe AGING (CERPOP) Institut Hospitalier Universitaire HealthAge Institut Hospitalier Universitaire HealthAge Institut Hospitalier Universitaire HealthAge Equipe AGING (CERPOP) Pôle Gériatrie [CHU Toulouse] Equipe AGING (CERPOP) Pôle Gériatrie [CHU Toulouse] Service Epidémiologie clinique et santé publique [CHU Toulouse] Equipe AGING (CERPOP) Ligue pour la protection des oiseaux (Franche-Comté) Institut Hospitalier Universitaire HealthAge Université Paris-Saclay CEA- Saclay Centre National de la Recherche Scientifique Service NEUROSPIN Building large instruments for neuroimaging: from population imaging to ultra-high magnetic fields NeuroSpin/GAIA (Brain Imaging and Data Science Lab) Service de Médecine Nucléaire - Pierre-Paul Riquet [CHU Toulouse] Communauté d'universités et établissements de Toulouse Toulouse NeuroImaging Center Institut Hospitalier Universitaire HealthAge Service Epidémiologie clinique et santé publique [CHU Toulouse] Equipe AGING (CERPOP)
• Publié dans Journals of Gerontology Series A: Biological Sciences and Medical Sciences le 01/01/2003

---

Résumé : Background This study aims to assess the evolution of cognitive performances over a 5-year follow-up period in community-dwelling older people with negative plasma p-tau181 levels and to determine whether frailty could discriminate between those who experience cognitive decline and those who do not, in the p-tau negative groups. Methods This is a 5-year analysis of the Multidomain Alzheimer Prevention Trial (MAPT) testing cognitive evolution among 503 community-dwelling individuals with available data on plasma p-tau181. Negative p-tau status was assigned according to 3 different cut-offs: amyloid-PET positivity (9.6 pg/mL), highest tertile for baseline p-tau181 distribution (10.9 pg/mL), and Alzheimer’s disease diagnosis prediction (12.4 pg/mL) cut-offs. Cognition was measured using a validated composite cognitive score derived from the Z-scores of 4 cognitive tests. Longitudinal changes from baseline in the composite cognitive score according to plasma p-tau181 status were compared using linear mixed models. Results In a population with an end-of-study median age of 79 years (interquartile range: 76–82), whatever the cut-off, the overall group with negative p-tau181 status did not develop cognitive decline over the follow-up. Among the p-tau181 negative groups, individuals who declined had a higher prevalence of frailty compared to those who did not decline. Conclusions Cognitive performance in older people with negative plasma p-tau181 levels remains stable over a 5-year period. This may suggest that older age alone, in the absence of positive biomarkers for brain pathology (or frailty), is not associated with cognitive decline. Frailty may increase vulnerability to the neuropathological burden associated with Alzheimer’s disease.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 08/07/2025
• Auteurs : Eimad ShotarBertrand MathonHenri SalleAymeric RouchaudCharbel MounayerNicolas BricoutJean-Paul LejeuneKevin JanotAymeric AmelotOlivier NaggaraAlexandre RouxStéphane GoutagnyAlexis GuédonEmmanuel HoudartHervé BrunelJean-François HakLucas TroudeHenry DufourAnne-Laure BernatTitien TuilierDamien BressonCaroline ApraMathilde FouetSimon EscalardDorian ChauvetKevin PrematSaid LebbahAgnès DechartresFrédéric ClarenconStéphanie LenckNader-Antoine SourourMahmoud ElhoranyPierre-Marie ChiaroniJulien AllardEric BarberisMathilde AubertinAdnan AltayebRobert BurnsSacha BensousanHaroun GhannouchiDamien ParatTom BoekenGonzague GuillaumetAlexandru DimanceaHugo TrebernAdrien BethBaptiste BonnetRomain CoudertYohan DucosGiulio Quarta ColossoEmily RiusXavier GuerraSamer SolimanClément PechinéLuca ScarciaVincent DegosAlice JacquensMehdi DrirJugurtha MathoutAnne Sophie MonteroEtienne LefevreMaximilien RichePauline MarijonMichel KalamaridesAlexandre CarpentierAnne-Laure BochAurélien NouetVincent ReinaBertrand BaussartHenri MalaizeWagih Ben HassenDenis TrystramHugo GortaisFinoana Laza NomenjanaharyChristine RodriguezJohan PalludEdouard DezamisEduardo ParragaHoussem FathallahAlessandro MoiraghiChiara BenevelloJean-Pierre Saint MauriceVittorio CivelliMarc-Antoine LabeyrieFrancesco ArpaiaMatteo FantoniRosaria AbbrittiGueorgui IakovlevMathieu FaillotHelene StaquetAdrien Ortiz CarleAlberic BoccoErwah KalsoumFiras FarhatRodrigue JayrRaphael BlancMichel PiotinWilliam BoisseauFrançois DelvoyeQuentin HolayJean-Philippe DesillesHocine RedjemStanislas SmajdaAmira Al-RaaisiSamiya Abi JaoudeJean Marc DelmasFrançois-Léopold MaisonSuzana SalemeGéraud ForestierClément GantoisLeslie LemnosEdouard GueyeBasile KerlerouxAnthony ReyreSébastien BoissonneauThomas GraillonFarah KaissarMikael MeyerAdamou ToutaGuillaume BaucherValentin AvinensThomas PersonnicAdrien MarchalMartin BretznerLucas GrenierMélodie-Anne KarnoubVictor LegrandHenri-Arthur LeroyBastier GougesAmelie ToubolAntoine DevalckeneerLouis ObledRabih AboukaisIulia Pecui-FlorianuGrégoire BoulouisDenis HerbreteauRichard BibiHéloise IferganFouzi BalaIlyess ZemmouraLouise Marie Terrier
• Organismes : Sorbonne Université Sorbonne Université AP-HP - Hôpital de la Pitié Salpêtrière Service de Neurochirurgie [CHU Limoges] Contrôle de l’Activation Cellulaire, Progression Tumorale et Résistance thérapeutique Service de Neuroradiologie interventionnelle [CHU Limoges] BIO-SANTÉ Service de Neuroradiologie interventionnelle [CHU Limoges] BIO-SANTÉ Centre Hospitalier Régional Universitaire [CHU Lille] Thérapies Assistées par Lasers et Immunothérapies pour l'Oncologie - U 1189 Département de Neurochirurgie[Lille] Service de neuroradiologie [CHRU Tours] Centre Hospitalier Régional Universitaire de Tours Institut de psychiatrie et neurosciences de Paris Groupe hospitalier universitaire Paris psychiatrie & neurosciences [Paris] Groupe hospitalier universitaire Paris psychiatrie & neurosciences [Paris] Biomarqueurs en imagerie : neuro développement et pathologies cérébrales Service de neurochirurgie [CHU Clichy] Variabilité de réponse aux Psychotropes Institut Pierre Louis d'Epidémiologie et de Santé Publique Service de Neuroradiologie [CHU Lariboisière] GHU AP-HP Nord - Université Paris Cité Service de Neuroradiologie [CHU Lariboisière] Assistance Publique - Hôpitaux de Marseille Hôpital de la Timone [CHU - APHM] Assistance Publique - Hôpitaux de Marseille Marseille medical genetics - Centre de génétique médicale de Marseille Institut Marseille Maladies Rares Service de neurochirurgie [CHU Marseille] Histoire naturelle de l'Homme préhistorique AP-HP - Hôpital Henri-Mondor Hôpital Foch [Suresnes] Physiologie et physiopathologie endocriniennes
• Publié dans JAMA Cardiology le 25/10/2020

---

Résumé : Importance Middle meningeal artery (MMA) embolization has been proposed as a potential treatment for chronic subdural hematoma (CSDH). Objective To assess the efficacy of MMA embolization in reducing the risk of CSDH recurrence at 6 months compared with standard care in patients who underwent an operation and were at high risk of CSDH recurrence. Design, Setting, and Participants Multicenter, open-label, randomized clinical trial with blinded end point assessment. Patients who underwent an operation for CSDH recurrence or a first CSDH episode at high risk of recurrence were recruited from July 2020 to March 2023 in 12 French neurosurgical or comprehensive neurosurgical and interventional neuroradiology centers. Last follow-up took place on November 2, 2023. Intervention Participants were randomized 1:1 to undergo MMA embolization with microparticles within 7 days of surgery (171 patients, intervention group) or standard medical care alone (171 patients, control group). Main Outcomes and Measures The primary end point was the rate of CSDH recurrence at 6 months assessed by an independent, blinded adjudication committee. There were 5 secondary end points, including rates of repeat surgery for homolateral CSDH recurrence during the 6-month follow-up period and embolization procedure–related complications. Results Among 342 randomized patients (median [IQR] age, 77 [68-83] years; 274 [80.1%] male), 308 (90.1%) completed the trial. The primary end point was observed in 24 of 162 (14.8%) and 33 of 157 (21.0%) patients in the intervention and control groups, respectively (after imputation: odds ratio, 0.64 [95% CI, 0.36-1.14]; adjusted absolute difference, −6% [95% CI, −14% to 2%]; P = .13). The groups did not significantly differ in any of the secondary end points. Repeat surgery was performed in 7 of 162 (4.3%) and 13 of 157 (8.3%) patients in the intervention and control groups ( P = .14), respectively. Minor and major embolization procedure–related complications occurred in 3 of 171 (1.8%) and 1 of 171 (0.6%) patients, respectively. Conclusions and Relevance In this randomized clinical trial, among patients who underwent an operation for CSDH recurrence or a first CSDH episode at high risk of recurrence, MMA embolization did not lead to a significantly lower rate of recurrence at 6 months compared with standard medical care alone. However, the magnitude of the effect estimate is consistent with other recent trials, including some that demonstrated the benefit of MMA embolization with nonadhesive liquid embolic agents, and these findings considered together may inform future studies and potential use of this therapeutic approach for CSDH management. Trial Registration ClinicalTrials.gov Identifier: NCT04372147

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 08/07/2025
• Auteurs : Derouin MargotAmazigh MokhtariEl Chérif IbrahimPierre-Éric LutzRaoul BelzeauxCynthia Marie-ClaireFrank BellivierBruno EtainCathy PhilippeAndree Delahaye-Duriez
• Organismes : Maladies neurodéveloppementales et neurovasculaires Maladies neurodéveloppementales et neurovasculaires Institut de Neurosciences de la Timone Institut des Neurosciences Cellulaires et Intégratives Douglas Mental Health University Institute [Montréal] Institut de Neurosciences de la Timone Département de Psychiatrie adulte [Hôpital de la Colombière - CHU Montpellier] Optimisation thérapeutique en Neuropsychopharmacologie Optimisation thérapeutique en Neuropsychopharmacologie Fondation FondaMental [Créteil] Département de Psychiatrie et de Médecine Addictologique Optimisation thérapeutique en Neuropsychopharmacologie Département de Psychiatrie et de Médecine Addictologique Building large instruments for neuroimaging: from population imaging to ultra-high magnetic fields Maladies neurodéveloppementales et neurovasculaires AP-HP - Hôpital Jean-Verdier Université Sorbonne Paris Nord

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 08/07/2025
• Auteurs : Eimad ShotarBertrand MathonHenri SalleAymeric RouchaudCharbel MounayerNicolas BricoutJean-Paul LejeuneKevin JanotAymeric AmelotOlivier NaggaraAlexandre RouxStéphane GoutagnyAlexis GuédonEmmanuel HoudartHervé BrunelJean-François HakLucas TroudeHenry DufourAnne-Laure BernatTitien TuilierDamien BressonCaroline ApraMathilde FouetSimon EscalardDorian ChauvetKevin PrematSaid LebbahAgnès DechartresFrédéric ClarençonStéphanie LenckNader-Antoine SourourMahmoud ElhoranyPierre-Marie ChiaroniJulien AllardEric BarberisMathilde AubertinAdnan AltayebRobert BurnsSacha BensousanHaroun GhannouchiDamien ParatTom BoekenGonzague GuillaumetAlexandru DimanceaHugo TrebernAdrien BethBaptiste BonnetRomain CoudertYohan DucosGiulio Quarta ColossoEmily RiusXavier GuerraSamer SolimanClément PechinéLuca ScarciaVincent DegosAlice JacquensMehdi DrirJugurtha MathoutAnne Sophie MonteroEtienne LefevreMaximilien RichePauline MarijonMichel KalamaridesAlexandre CarpentierAnne-Laure BochAurélien NouetVincent ReinaBertrand BaussartHenri MalaizeWagih Ben HassenDenis TrystramHugo GortaisFinoana Laza NomenjanaharyChristine RodriguezJohan PalludEdouard DezamisEduardo ParragaHoussem FathallahAlessandro MoiraghiChiara BenevelloJean-Pierre Saint MauriceVittorio CivelliMarc-Antoine LabeyrieFrancesco ArpaiaMatteo FantoniRosaria AbbrittiGueorgui IakovlevMathieu FaillotHelene StaquetAdrien Ortiz CarleAlberic BoccoErwah KalsoumFiras FarhatRodrigue JayrRaphael BlancMichel PiotinWilliam BoisseauFrançois DelvoyeQuentin HolayJean-Philippe DesillesHocine RedjemStanislas SmajdaAmira Al-RaaisiSamiya Abi JaoudeJean Marc DelmasFrançois-Léopold MaisonSuzana SalemeGéraud ForestierClément GantoisLeslie LemnosEdouard GueyeBasile KerlerouxAnthony ReyreSébastien BoissonneauThomas GraillonFarah KaissarMikael MeyerAdamou ToutaGuillaume BaucherValentin AvinensThomas PersonnicAdrien MarchalMartin BretznerLucas GrenierMélodie-Anne KarnoubVictor LegrandHenri-Arthur LeroyBastier GougesAmelie ToubolAntoine DevalckeneerLouis ObledRabih AboukaisIulia Pecui-FlorianuGrégoire BoulouisDenis HerbreteauRichard BibiHéloise IferganFouzi BalaIlyess ZemmouraLouise Marie Terrier
• Organismes : Service de neurochirurgie [CHU Clichy] Variabilité de réponse aux Psychotropes Health data-and model-driven approaches for Knowledge Acquisition
• Publié dans JAMA Cardiology le 25/10/2020

---

Résumé : Importance Middle meningeal artery (MMA) embolization has been proposed as a potential treatment for chronic subdural hematoma (CSDH). Objective To assess the efficacy of MMA embolization in reducing the risk of CSDH recurrence at 6 months compared with standard care in patients who underwent an operation and were at high risk of CSDH recurrence. Design, Setting, and Participants Multicenter, open-label, randomized clinical trial with blinded end point assessment. Patients who underwent an operation for CSDH recurrence or a first CSDH episode at high risk of recurrence were recruited from July 2020 to March 2023 in 12 French neurosurgical or comprehensive neurosurgical and interventional neuroradiology centers. Last follow-up took place on November 2, 2023. Intervention Participants were randomized 1:1 to undergo MMA embolization with microparticles within 7 days of surgery (171 patients, intervention group) or standard medical care alone (171 patients, control group). Main Outcomes and Measures The primary end point was the rate of CSDH recurrence at 6 months assessed by an independent, blinded adjudication committee. There were 5 secondary end points, including rates of repeat surgery for homolateral CSDH recurrence during the 6-month follow-up period and embolization procedure–related complications. Results Among 342 randomized patients (median [IQR] age, 77 [68-83] years; 274 [80.1%] male), 308 (90.1%) completed the trial. The primary end point was observed in 24 of 162 (14.8%) and 33 of 157 (21.0%) patients in the intervention and control groups, respectively (after imputation: odds ratio, 0.64 [95% CI, 0.36-1.14]; adjusted absolute difference, −6% [95% CI, −14% to 2%]; P = .13). The groups did not significantly differ in any of the secondary end points. Repeat surgery was performed in 7 of 162 (4.3%) and 13 of 157 (8.3%) patients in the intervention and control groups ( P = .14), respectively. Minor and major embolization procedure–related complications occurred in 3 of 171 (1.8%) and 1 of 171 (0.6%) patients, respectively. Conclusions and Relevance In this randomized clinical trial, among patients who underwent an operation for CSDH recurrence or a first CSDH episode at high risk of recurrence, MMA embolization did not lead to a significantly lower rate of recurrence at 6 months compared with standard medical care alone. However, the magnitude of the effect estimate is consistent with other recent trials, including some that demonstrated the benefit of MMA embolization with nonadhesive liquid embolic agents, and these findings considered together may inform future studies and potential use of this therapeutic approach for CSDH management. Trial Registration ClinicalTrials.gov Identifier: NCT04372147

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 07/07/2025
• Auteurs : Adrienn KelemenMagalie UyttewaalCsaba MáthéPhilippe AndreyDavid BouchezMartine Pastuglia
• Organismes : Institut Jean-Pierre Bourgin - Sciences du végétal University of Debrecen Institut Jean-Pierre Bourgin - Sciences du végétal Institut Jean-Pierre Bourgin - Sciences du végétal Institut Jean-Pierre Bourgin - Sciences du végétal Institut Jean-Pierre Bourgin - Sciences du végétal
• Publié dans New Phytologist le 01/11/2020

---

Résumé : Posttranslational modification of histones during the cell cycle is a major process controlling many aspects of cell division. Among the variety of histone modifications, mitotic phosphorylation of histone H3 at serine 10 (H3S10ph) plays a crucial role, particularly in proper chromosome segregation. Here we aimed at precisely quantifying this phosphorylation dynamics during mitosis in plant cells in order to reveal molecular pathways involved in this process. We describe an analysis pipeline based on 3D image analysis that allows to semiautomatically quantify H3S10ph in mitotic Arabidopsis root cells. We also developed a new method for the compensation of signal attenuation in Z, based on measurement of objects of interest themselves. We show that this new attenuation correction method allows significant gains in accuracy and statistical power. Using this pipeline, we were able to reveal small H3S10ph differences between cells treated with hesperadin, an inhibitor of an H3S10ph kinase, or between Arabidopsis mutants affected in PP2A phosphatase activity. This tool opens new avenues to explore such regulatory pathways in plants, using the wealth of genetic materials available in Arabidopsis. It can also be applied to study other histone posttranslational modifications and more generally to any discrete 3D signals.

---

Fichiers liés : 2025_Kelemen-nph70365.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 07/07/2025
• Auteurs : Xiaojun LiPhilippe CiaisFrédéric FrappartKlaus ScipalSassan S SaatchiHui YangClément AlbergelXiangzhuo LiuYuqing LiuWigneron J.-P.Huan WangZanpin XingAurelien de TruchisJean-Pierre Wigneron
• Organismes : Interactions Sol Plante Atmosphère Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] Contrôles des cycles biogéochimiques terrestres Interactions Sol Plante Atmosphère ESA Centre for Earth Observation Southwest University [Chongqing] Peking University [Beijing] European Centre for Space Applications and Telecommunications Interactions Sol Plante Atmosphère Interactions Sol Plante Atmosphère Interactions Sol Plante Atmosphère Peking University [Beijing] Interactions Sol Plante Atmosphère Technische Universität Munchen = Technical University Munich = Université Technique de Munich Interactions Sol Plante Atmosphère
• Publié dans Scientific Data le 29/10/2020

---

Résumé :

---

Fichiers liés : Scientific data.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 04/07/2025
• Auteurs : Sofía CorreaMathieu ThomasJustine LepagneulAubin DémontéC.R. B.A.Pierre BerthetJean-Philippe ClairChristian DalmassoCédric MaryDenis MignardHonorine PérinoMarie-Pierre RépécaudStéphane RouvèsLéa BernardGustave FradinCamille Vindras-FouilletJean-François VianOlivier HamantMarie-Thérèse Charreyre
• Organismes : Reproduction et développement des plantes Ingénierie des Matériaux Polymères Amélioration génétique et adaptation des plantes méditerranéennes et tropicales Département Systèmes Biologiques Amélioration génétique et adaptation des plantes méditerranéennes et tropicales Département Systèmes Biologiques Ingénierie des Matériaux Polymères Reproduction et développement des plantes Agroécologie et Environnement = Agroecology and Environment Centre de Ressources de Botanique Appliquée GAEC Ferme des Pierres Gardées Graines de l’Ain Association Régionale pour le Développement de l’Emploi Agricole et Rural Auvergne-Rhône-Alpes Association Régionale pour le Développement de l’Emploi Agricole et Rural Auvergne-Rhône-Alpes Le Croissant Fertile Le Croissant Fertile GAEC Ferme des Pierres Gardées GAEC La Viry Association Régionale pour le Développement de l’Emploi Agricole et Rural Auvergne-Rhône-Alpes Centre d’Ecologie Fonctionnelle et Evolutive Amaranthus Agroécologie et Environnement = Agroecology and Environment Reproduction et développement des plantes Ingénierie des Matériaux Polymères
• Publié dans Quantitative Plant Biology le 04/10/2022

---

Résumé : Expanding crop diversity is essential to address the imminent challenges of agriculture. This is especially true for organic farming, which relies on locally adapted species and varieties. Recently, participatory research approaches have emerged as effective means to support this endeavour. In this study, we collaborated with several stakeholders in the Lyon region, France, to evaluate three minor species related to common wheat (Triticum aestivum subsp . aestivum): einkorn ( Triticum monococcum subsp . monococcum), emmer (Triticum turgidum subsp . dicoccum) and spelt (Triticum aestivum subsp. spelta L. Thell). First, we assessed the agronomic characteristics of each species, highlighting a distinction of einkorn that was associated with high tillering, high protein content, a long phenological cycle, small kernels and low relative yields. Second, we compared intra-species variabilities, revealing greater variation in emmer and spelt. Lastly, outcomes of the participatory approach, including testing adaptive methods and fostering collective learning, may interest other participatory research groups.

---

Fichiers liés : Correa_a situated study on hulled wheats_QPB 2025.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 04/07/2025
• Auteurs : Zacharie Barrou DumontSimon GascoinJordi IngladaAndreas DietzJonas KöhlerMatthieu LafaysseDiego MonteiroCarlo CarmagnolaArthur BayleJean-Pierre DedieuOlivier HagolleP. Choler
• Organismes : Centre d'études spatiales de la biosphère Centre d'études spatiales de la biosphère Centre d'études spatiales de la biosphère Centre National d'Études Spatiales [Toulouse] University Hospital Leipzig = Universitätsklinikum Leipzig Eidgenössische Technische Hochschule - Swiss Federal Institute of Technology [Zürich] Centre d'Etudes de la Neige Centre d'Etudes de la Neige ABEST Horizons Centre d'Etudes de la Neige Laboratoire d'Ecologie Alpine Institut d'Asie Orientale Institut des Géosciences de l’Environnement Centre d'études spatiales de la biosphère Centre National d'Études Spatiales [Toulouse] Laboratoire d'Ecologie Alpine
• Publié dans The Cryosphere le 28/10/2020

---

Résumé : Abstract. Information on the spatial–temporal variability of seasonal snow cover duration over long time periods is critical for studying the responses of mountain ecosystems to climate change. However, this information is often lacking due to the sparse distribution of in situ observations or the lack of adequate remote sensing products. Here, we combined snow cover data from 10 different optical platforms, i.e. SPOT (Satellites Pour l'Observation de la Terre) 1–5, Landsat 5–8, and Sentinel-2A and Sentinel-2B, to build a time series of the annual snow melt-out day (SMOD, i.e. the first day of no snow cover) at 20 m resolution across the French Alps and Pyrenees (43 × 103 km2). We evaluated the pixel-wise accuracy of the computed SMOD using in situ snow measurements at 276 stations. We found that the residuals are unbiased (median error of 1 d) despite a dispersion (RMSE of 28 d), which suggests that this dataset can be used to study SMOD trends after spatial aggregation. We found average reductions of 21.4 d (5.78 d per decade) over the French Alps and 16 d (4.33 d per decade) over the Pyrenees over the period 1986–2023. The SMOD reduction is robust and significant in most parts of the French Alps and can reach 1 month above 3000 m. The trends are less consistent and more spatially variable in the Pyrenees. This dataset is available for future studies of mountain ecosystem changes and is updated every year using Sentinel-2 data.

---

Fichiers liés : tc-19-2407-2025.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 02/07/2025
• Auteurs : Maxence JamesElise NexerAlexandra GirondéCéline Masclaux‐daubresseAnne MarmagneJacques TrouveriePhilippe Etienne
• Organismes : Université de Caen Normandie Institut Jean-Pierre Bourgin - Sciences du végétal Institut Jean-Pierre Bourgin - Sciences du végétal Ecophysiologie Végétale, Agronomie et Nutritions NCS Ecophysiologie Végétale, Agronomie et Nutritions NCS Université de Caen Normandie
• Publié dans Planta le 31/10/2020

---

Résumé :

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/07/2025
• Auteurs : Benoit YouSébastien CouraudPhilippe CeruseLionel BadetPhilippe PaparelAlice DurandMarielle GuilletPhilippe MerleGaelle LescuyerCharles-André PhilipFrançois DucrayMathieu PiocheLionel KarlinJean-Christophe LifanteOlivier GlehenPierre-Adrien BolzeMarion ChauvenetCarole Langlois-JacquesFabien SubtilMarie PiecykAurore CarrotDominique JoubertAlexandre PrieurBerengere VireSara CalattiniLea Payen
• Organismes : Institut de Cancérologie des Hospices Civils de Lyon Centre pour l'innovation en cancérologie de Lyon Institut de Cancérologie des Hospices Civils de Lyon Centre pour l'innovation en cancérologie de Lyon Institut de Cancérologie des Hospices Civils de Lyon Centre pour l'innovation en cancérologie de Lyon Institut de Cancérologie des Hospices Civils de Lyon Hôpital Edouard Herriot [CHU - HCL] Institut de Cancérologie des Hospices Civils de Lyon Institut de Cancérologie des Hospices Civils de Lyon Hôpital Edouard Herriot [CHU - HCL] Institut de Cancérologie des Hospices Civils de Lyon Hôpital Edouard Herriot [CHU - HCL] Institut de Cancérologie des Hospices Civils de Lyon Hôpital Edouard Herriot [CHU - HCL] Institut de Cancérologie des Hospices Civils de Lyon Centre pour l'innovation en cancérologie de Lyon Institut de Cancérologie des Hospices Civils de Lyon Hôpital Femme Mère Enfant [CHU - HCL] Institut de Cancérologie des Hospices Civils de Lyon Institut de Cancérologie des Hospices Civils de Lyon Hôpital Edouard Herriot [CHU - HCL] Institut de Cancérologie des Hospices Civils de Lyon Centre Hospitalier Lyon Sud [CHU - HCL] Research on Healthcare Performance Institut de Cancérologie des Hospices Civils de Lyon Institut de Cancérologie des Hospices Civils de Lyon Centre Hospitalier Lyon Sud [CHU - HCL] Institut de Cancérologie des Hospices Civils de Lyon Institut de Cancérologie des Hospices Civils de Lyon Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 Hospices Civils de Lyon Service de Biostatistiques [Lyon] Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 Service de Biostatistiques [Lyon] Hospices Civils de Lyon Institut de Cancérologie des Hospices Civils de Lyon Hospices Civils de Lyon Institut de Cancérologie des Hospices Civils de Lyon Institut de Cancérologie des Hospices Civils de Lyon Institut de Cancérologie des Hospices Civils de Lyon Centre pour l'innovation en cancérologie de Lyon Laboratoire de Biologie Médicale MultiSites [Bron]
• Publié dans Biomarker Research le 25/10/2020

---

Résumé : Abstract Background hPG 80 (circulating progastrin), initially recognized for its oncogenic properties due to its direct link to the Wnt signaling pathway, is secreted by cancer cells and detectable in the blood of cancer patients. The ONCOPRO centralized case-control study (NCT03787056) was designed to prospectively evaluate the diagnostic utility of hPG 80 in patients with 16 different types of cancer. Methods hPG 80 levels were measured in 421 patients with 16 newly diagnosed cancers (median age 65.6 years old) using the DxPG80.Lab kit (Biodena Care). The diagnostic performance of hPG 80 (the primary endpoint) was assessed by comparing baseline hPG 80 levels in cancer patients with those of 330 asymptomatic aged-matched healthy subjects from the general population. Results Between 2018 and 2022, a total of 506 cancer patients were enrolled in the study, with 421 assessable across 16 distinct cancer cohorts. hPG 80 concentrations were significantly higher in cancer patients compared to the healthy population (median 3.8 [IQR: 1.0-11.1] vs. 1.9 [IQR: 0.6–4.2] pM, P < 0.0001). hPG80 levels were not impacted by renal failure, liver dysfunction, or cancer-associated inflammation. The diagnostic accuracy in cancer patients was ROC AUC 0.63, 95% CI = [0.59–0.67]. The highest diagnostic accuracy was seen in patients with lung cancer (AUC 0.75, 95% CI [0.68–0.82]; specificity = 88% for hPG 80 > 7.73 pM in patients aged > 58 years old) and hepatocellular carcinoma HCC (ROC AUC 0.75, 95% CI [0.66-083]; specificity = 88% for hPG 80 > 7.73 pM in patients aged > 58 years old). Conclusions This large prospective study confirms that cancer patients have significantly higher hPG 80 blood concentration compared to the healthy population. Incorporating this straightforward ELISA assay into screening programs is warranted. Trial registration NCT03787056.

---

Fichiers liés : 40364_2025_Article_793.pdf

---

Source